High-Dose Cytarabine Maximizes CD34 Cell Yield Without Improving Survival in PCNSL High-dose cytarabine achieved 100% stem cell mobilization success in PCNSL patients undergoing autologous transplantation.

High-dose cytarabine (HD-Ara-C)-based mobilization achieved universal stem cell collection and the highest CD34⁺ yields in primary central nervous system lymphoma (#PCNSL), yet did not confer a progression-free survival advantage.

Read more: https://bit.ly/4rGQcuL

#RareDisease #Lymphoma

💡 Discover 3 Facts About Primary Central Nervous System Lymphoma (#PCNSL)

Learn more at our Resource Page: https://bit.ly/4pR6elO

#WorldCancerDay #RareCancer #RareDisease

🟥 World AIDS Day

Today we honor those affected by #HIV and raise awareness of conditions linked to it — including #PCNSL, a #RareCancer historically seen more often in advanced HIV.

#WorldAIDSDay #HIVAwareness #RareDisease #HealthEquity #EndTheStigma #MedSky

Management of primary central nervous system lymphoma and coexisting heart failure with reduced ejection fraction: a narrative review Explore current treatments for primary central nervous system lymphoma, including those involving high-dose methotrexate, and their implications for patients with heart failure with reduced ejection…

Explore current treatments for primary central nervous system lymphoma, including those involving high-dose #methotrexate, and their implications for patients with #HFrEF.

👉https://buff.ly/hHicXoQ

#NeuroSky #PCNSL

I am so proud.

You see, my wife has brain cancer. She used to be a voracious reader. She used to teach English. Now, she is in a clinical trial that has kept her stable for 3 years.

She just finished reading her first book.
#PCNSL #Lymphoma

R2-MTX Regimen Shows Potential in Newly Diagnosed Patients With PCNSL - Oncology Nurse Advisor In addition to a 69.4% CR rate, the team observed good tolerability of the R2-MTX regimen, suggesting its suitability for older or less fit patients.

HD-MTX with R2-MTX shows promise as a treatment for newly diagnosed patients with #PCNSL. From @rarediseaseadvisor.bsky.social.

https://bit.ly/41vP8zu

#lymsm

Novel Agents Improve Complete Remission but Fail to Extend Survival in PCNSL The R2-MTX and POR/ROM regimens achieved higher response rates than R-MTX but showed no statistical advantage in overall survival.

In patients with newly diagnosed #PCNSL, combining HD-MTX with novel small molecule agents improved complete remission rates but did not result in statistically significant differences in PFS or OS compared with HD-MTX and rituximab alone. From @rarediseaseadvisor.bsky.social.

📣 New ESMO #ClinicalPracticeGuideline on #lymphomas: evidence-based recommendations for all major #lymphoma subtypes, updated as needed as an ESMO Living Guideline, reflecting developments in Tx.
#DLBCL #PCNSL #FollicularLymphoma #HodgkinLymphoma #ESMOGuidelines

🔗 buff.ly/2ZYJc2c

Recurrent PCNSL Signaled by FLAIR Hyperintensity Without Enhancement Despite normal results on CSF fluid analysis, a stereotactic biopsy revealed PCNSL recurrence.

Researchers have reported a case of recurrent primary central nervous system #lymphoma that demonstrated only mild 18F-FDG PET uptake on relapse. From @rarediseaseadvisor.bsky.social.

bit.ly/4kz1o91

#PCNSL #lymsm

Today is a special day. On this day in 2022 my wife was diagnosed with a very rare and agressive brain cancer.
She's had is all & now She's in a trial for a new drug & it has kept her stable for 20+ mo.

Pls join me in wishing her a happy 3rd anniversary.
#pcnsl #lymphoma #cancer #science ❤️🔄

Curis Provides Business Update and Financial Results for Q4 2024 Curis, Inc. has announced its fourth quarter 2024 business update, paving the way for accelerated drug approval discussions in the US and EU.

Curis Provides Business Update and Financial Results for Q4 2024 #USA #Lexington #Curis #emavusertib #PCNSL

Molecular Mechanisms and Therapeutic Prospects of Immunotherapy and Targeted Therapy in Primary Central Nervous System Lymphoma - Feb 6, 2025
@journals.sagepub.com

journals.sagepub.com/doi/10.1177/...

#nonHodgkinslymphoma #PCNSL #cancertreatment #cancerresearch

Distinct epigenetic and transcriptional profiles of Epstein-Barr virus (EBV) positive and negative primary CNS lymphomas AbstractBackground. Epstein-Barr virus (EBV)+ and EBV- primary CNS lymphomas (PCNSL) carry distinct mutational landscapes, but their transcriptional and ep

Distinct epigenetic and transcriptional profiles in EBV + | - #PCNSL Take a look at the recent great work by @LeonKaulen and @FelixSahm & colleagues @HDNeurooncology

track.smtpsendmail.com/9032119/c?p=...